Royalty Pharma Plc (RPRX 1.24%), a leader in acquiring royalties on biopharmaceutical products, released second quarter results on August 6, 2025. The most notable news: Royalty Receipts—its closest revenue proxy—rose 11% to $672 million but landed just under the $672.99 million analyst estimate (GAAP). Portfolio Receipts, a non-GAAP metric which tracks cash inflows from all royalties and milestones, increased 20% to $727 million. The quarter highlighted strong cash generation, a major partnership with Revolution Medicines, and a continued shift toward a more diversified portfolio. Despite a marginal revenue miss (GAAP) and some product headwinds, the quarter reinforced the company’s robust growth and ongoing evolution. Management responded by raising full-year 2025 Portfolio Receipts guidance to $3,050 million to $3,150 million.
| Metric | Q2 2025 | Q2 2025 Estimate | Q2 2024 | Y/Y Change |
|---|---|---|---|---|
| EPS (Non-GAAP) | N/A | $1.03 | N/A | N/A |
| Revenue – Royalty Receipts | $672 million | $672.99 million | $605 million | 11.1 % |
| Portfolio Receipts | $727 million | $608 million | 19.6 % | |
| Adjusted EBITDA (Non-GAAP) | $633 million | $560 million | 13.0 % | |
| Portfolio Cash Flow (Non-GAAP) | $641 million | $574 million | 11.7 % |
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.
Understanding Royalty Pharma’s Business and Recent Focus
Royalty Pharma acquires rights to future royalty streams on approved and late-stage biopharma products. By doing so, it earns a share of sales from medicines across various fields, while the original drug developer handles research, production, and marketing.
This approach allows it to draw steady income from best-selling therapies, with limited direct involvement in clinical development. Key success factors include disciplined acquisition of new royalty assets, portfolio diversification to reduce dependency on individual drugs, and effective capital allocation, such as share buybacks and dividends. The company’s strategic focus in 2025 has been deploying capital in late-stage innovation, maintaining a balanced portfolio, and integrating its external manager to increase efficiency.
Quarter in Detail: Highlights and Key Developments
During the quarter, Portfolio Receipts (non-GAAP) climbed 20% year over year, outpacing Royalty Receipts due to a significant jump in milestone and contractual payments (Portfolio Receipts, a non-GAAP metric, increased by 20% to $727 million, while Royalty Receipts grew 11% to $672 million). This boost came from major assets including Voranigo, a gene therapy royalty newly added to the portfolio, as well as flagship therapies Trelegy (inhaled medicine for chronic lung disease), Evrysdi (spinal muscular atrophy therapy), and Tremfya (inflammatory disease monoclonal antibody). Each grew by double-digit percentages, or in the case of Voranigo, represented a new stream entirely.
Some established assets experienced pressure. The cystic fibrosis franchise, a lead rare disease royalty, remained flat year over year. Tysabri (monoclonal antibody for multiple sclerosis) and Imbruvica (oral cancer therapy) both posted declining royalty receipts, with decreases of 13% and 11%, respectively. Notably, a royalty contract dispute with Vertex over Alyftrek (new cystic fibrosis treatment) introduced uncertainty around receipts for this group of products. The company has initiated dispute resolution but highlighted that cystic fibrosis therapies remain core contributors for the foreseeable future.
Strategically, capital deployment was significant. $595 million in capital deployment went toward new deals, largely an innovative partnership with Revolution Medicines. This agreement—up to $2 billion, including a $1.25 billion synthetic royalty on the late-stage oncology candidate daraxonrasib—was announced in June 2025 and aligns with the company’s stated aim to back high-impact, late-stage therapies. Milestone payments also spiked, adding $56 million in receipts compared to just $3 million the previous year (non-GAAP). On the internal operations front, Royalty Pharma underwent a major change by internalizing RP Management, its external manager. The shareholder vote in May saw near-unanimous support, marking a move toward tighter integration, cost streamlining, and improved capital discipline.
The quarter also saw active use of cash for shareholder returns. The company repurchased eight million shares for $277 million, with $1 billion returned via buybacks in the first half of 2025. Cash conversion remained robust, but net cash provided by operating activities (GAAP) dropped year over year, a result of one-time development and milestone outlays rather than a persistent decline in profitability.
Outlook: Guidance and What to Watch
Management raised full-year 2025 Portfolio Receipts guidance to $3.05–$3.15 billion, now representing 9% to 12% growth, compared to the previous 6% to 12% range for Portfolio Receipts guidance. It also downwardly revised expected costs (operating and professional) to 9%–9.5% of Portfolio Receipts, citing efficiency wins from the now-integrated management structure. Interest expense was adjusted upward to $275 million, as reflected in management's full-year guidance in light of recent financing associated with the internalization transaction.
For the next few quarters, the outcome of the Vertex cystic fibrosis royalty dispute is central, given the franchise's size in the company portfolio. Investors will also watch for continued trends in operating costs, further deal announcements, and updates from clinical progress in partnered development programs such as daraxonrasib, litifilimab (an antibody therapy for lupus), aficamten (cardiomyopathy drug), and trontinemab (targeted for Alzheimer’s disease). Royalty Pharma does pay a dividend.
Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted.
